Angion Announces Participation in Upcoming Investment Conference

Rhea-AI Summary

Angion Biomedica Corp. (NASDAQ:ANGN) announced its participation in the upcoming Shareholder Equity Conference, scheduled for April 21, 2022, at 11:30 AM ET. The event will be a virtual fireside chat format, allowing investors to engage directly with management. Angion focuses on developing therapies for fibrotic diseases, with its leading candidate, ANG-3070, currently in a Phase 2 trial for kidney diseases. A webcast of the event will be available on their website, remaining archived for 30 days.

Positive

• Participation in a key investor conference may enhance company visibility.
• ANG-3070 is in a Phase 2 trial, indicating progress in drug development for fibrotic diseases.

Negative

• None.

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Angion’s President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually. The presentation will be a fireside chat format and investors will have the opportunity to ask management questions during the live presentation. Details are as follows:

Shareholder Equity Conference (Virtual)

• Thursday, April 21, 2022 at 11:30 AM ET
  

A webcast of the event will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.

About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in JUNIPER, a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition. For more information, please visit www.angion.com. 

Contact
David D. Miller
Sr. Director of Communications & Investor Relations
investors@angion.com 

FAQ

What is Angion Biomedica's upcoming event on April 21, 2022?

Angion Biomedica will participate in the virtual Shareholder Equity Conference on April 21, 2022, at 11:30 AM ET.

What is ANG-3070?

ANG-3070 is Angion Biomedica's lead product candidate, a selective oral tyrosine kinase receptor inhibitor targeting fibrotic kidney and lung diseases.

What trial is ANG-3070 currently involved in?

ANG-3070 is currently involved in the JUNIPER Phase 2 trial, focusing on primary proteinuric kidney diseases.

How can I access the Shareholder Equity Conference webcast?

The webcast can be accessed through Angion's events and presentations page on their website and will remain available for about 30 days.